Multidisciplinary Team (MDT) follow-up consultation fee
Other
≈ ¥300-800
(≈ $45-115)
45 min
Disclaimer: This site is a medical service platform; some page content is AI-assisted. Health-related information does not constitute medical advice. If you have any questions, please consult a healthcare professional. See full disclaimer
Description
Estimated cost for Multidisciplinary Team (MDT) follow-up consultation fee at general public hospitals in China is about ¥210-640, and at Grade 3A hospitals about ¥300-800, varying by hospital tier and region.
Main Uses
The MDT follow-up consultation fee covers the coordinated, longitudinal evaluation of complex or refractory cases by a team of specialists (e.g., oncology, radiology, pathology, surgery, nursing, palliative care) to refine diagnosis, reassess treatment response, adjust multimodal therapy plans, address adverse effects, support shared decision-making, and facilitate transitions of care (e.g., from active treatment to surveillance or hospice). It is primarily used in oncology, neurology, rare diseases, complex geriatrics, and post-transplant management.
Normal Range
Not applicable. 'Multidisciplinary Team (MDT) Follow-up Consultation Fee' is a healthcare service charge, not a laboratory or physiological measurement; therefore, it has no biological normal range or numerical reference values.
Low Values - Possible Causes
N/A — This is a billing item, not a clinical biomarker. A 'low fee' may reflect institutional pricing policies, regional healthcare subsidies, insurance coverage tiers, patient eligibility for financial assistance, or administrative coding errors — not a clinical abnormality.
High Values - Possible Causes
N/A — As a service fee, elevated amounts may result from inclusion of premium specialist participation (e.g., senior oncologists or rare-disease experts), extended consultation duration, integration of advanced diagnostics review (e.g., genomic reports or cross-modality imaging synthesis), hospital-tier surcharges (e.g., Class III Grade A hospitals in China), or private/overseas MDT program structures — not pathological conditions.